The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- The HAS recommends generalizing screening for sickle cell disease to all newborns Nov 15, 2022
- Swine flu : this virus G4 that is of concern Jul 2, 2020
- WHO identifies pathogens that may cause future pandemics Nov 21, 2022
- In 2023, works on the Curacautín Hospital would resume after the bankruptcy of Claro, Vicuña and Valenzuela Nov 21, 2022
- Rospotrebnadzor assessed the duration of breathing problems after COVID-19 Aug 29, 2021
- Covid infections continue to skyrocket in the Region, with 444 new positives and more than 2,400 active cases Jul 15, 2021
- Recommendations for Safe and Effective Breastmilk Smoothing Foods Apr 16, 2021